Close Menu

NEW YORK (360Dx) – Arquer Diagnostics announced today that it has been awarded a  £70,000 ($86,038) grant from Innovate UK to prepare for a clinical study of its ELISA-based noninvasive prostate cancer test.

The test — called MCM5-ELISA — detects minichromosome maintenance, a protein biomarker of dividing cancer cells. The planned study will evaluate the test using urine and semen samples from up to 100 patients and help the company design a larger clinical trial that is expected to start later this year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.